Survival and recurrence
MST, gastric cancer
METASTASES, GASTRIC CANCER
The median follow-up was 44.0 months (3–65 months). The mean survival time (MST) of the 134 patients was 51.4 months (95% confidence interval [CI] 48.0–55.0 months).The estimated 3-year OS rates were 73.9% and 77.6% for the HIPEC group and non-HIPEC group, respectively, and the difference was not statistically significant (Overall survival of patients with advanced gastric cancer according to different treatmentsDisease-free survival of patients with advanced gastric cancer according to different treatmentsA total of 53 (39.6%) patients developed distant metastases during the follow-up, including 18 (26.9%) patients in the HIPEC group and 35 (52.2%) patients in the non-HIPEC group, with a statistically significant difference between the two groups (Sites of metastases in the HIPEC group and the non-HPIEC group